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AbstrACt
Objectives Whether unintended discontinuation of 
common, evidence-based, long-term medication occurs 
after hospitalisation; what factors are associated with 
unintended discontinuation; and whether the presence 
of documentation of medication at hospital discharge 
is associated with continuity of medication in general 
practice.
Design Retrospective cohort study between 2012 and 
2015.
setting Electronic records and hospital supplied 
discharge notifications in 44 Irish general practices.
Participants 20 488 patients aged 65 years or more 
prescribed long-term medication for chronic conditions.
Primary and secondary outcomes Discontinuity of four 
evidence-based medication drug classes: antithrombotic, 
lipid-lowering, thyroid replacement drugs and respiratory 
inhalers in hospitalised versus non-hospitalised patients; 
patient and health system factors associated with 
discontinuity; impact of the presence of medication in the 
hospital discharge summary on continuity of medication in 
a patient’s general practitioner (GP) prescribing record at 
6 months follow-up.
results In patients admitted to hospital, medication 
discontinuity ranged from 6%–11% in the 6 months 
posthospitalisation. Discontinuity of medication is 
significantly lower for hospitalised patients taking 
respiratory inhalers (adjusted OR (AOR) 0.63, 95% CI (0.49 
to 0.80), p<0.001) and thyroid medications (AOR 0.62, 
95% CI (0.40 to 0.96), p=0.03). There is no association 
between discontinuity of medication and hospitalisation for 
antithrombotics (AOR 0.95, 95% CI (0.81 to 1.11), p=0.49) 
or lipid lowering medications (AOR 0.92, 95% CI (0.78 to 
1.08), p=0.29). Older patients and those who paid to see 
their GP were more likely to experience increased odds of 
discontinuity in all four medicine groups. Less than half 
(39% to 47.4%) of patients had medication listed on their 
hospital discharge summary. Presence of medication on 
hospital discharge summary is significantly associated 
with continuity of medication in the GP prescribing record 
for lipid lowering medications (AOR 1.64, 95% CI (1.15 to 
2.36), p=0.01) and respiratory inhalers (AOR 2.97, 95% CI 
(1.68 to 5.25), p<0.01).
Conclusion Discontinuity of evidence-based long-term 
medication is common. Increasing age and private medical 
care are independently associated with a higher risk of 
medication discontinuity. Hospitalisation is not associated 
with discontinuity but less than half of hospitalised 
patients have medication recorded on their hospital 
discharge summary.
IntrODuCtIOn
Older patients are more likely to be prescribed 
multiple medications, have multiple chronic 
conditions and experience increasing 
number of transitions of care.1–3 Adherence 
to clinically appropriate, evidence-based 
therapies is important for lowering the risk 
of progression and complications related to 
their underlying chronic conditions.
Poor coordination of transitions of care is 
associated with adverse drug events, rehos-
pitalisation and discrepancies in medication 
lists.4–9 Disruptions in medication conti-
nuity following hospitalisation have been 
reported.10–13 In particular, omission of medi-
cation with known benefit has been noted in 
prescribing errors at discharge.14–18 Previous 
studies have primarily examined large 
dispensing and/or administrative databases 
post hospitalisation to record the outcome of 
‘discontinuity’.10–13 19 Hospitalisation giving 
rise to discontinuity may be attributable to 
prescribing errors at discharge (eg, omissions, 
strengths and limitations of this study
 ► This study includes prescribing data from a diverse 
group of general practices that includes non-fee and 
fee-paying patients.
 ► We examined the impact of hospitalisation on conti-
nuity of evidence-based, long term medication after 
discharge using a novel data collection technique 
accessing general practitioner prescribing records 
(as opposed to pharmacy dispensing records), codi-
fied chronic disease information and hospital provid-
ed discharge summary information.
 ► We had no information on reasons for hospitalisa-
tion or therapeutic intent in terms of discontinuing 
medication.
 ► We examined a limited number of medication groups 
and did not report on patient related-outcomes.
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communication issues), disruption in the prescribing 
process at the general practitioner (GP) level, failure or 
error in dispensing at the pharmacy level or the multi-
tude of reasons for patient non-adherence. It is unclear 
where and why this discontinuity arises. There has been 
limited assessment of the immediate impact of hospitalisa-
tion on medication omission at hospital discharge which 
in turn, influences general practice repeat prescribing 
records.20–24
Aim and objectives
The aim of this study was to determine whether the 
potentially unintentional discontinuation of common, 
evidence-based medications for chronic diseases occurs 
after hospitalisation among older community dwelling 
adults. The medicine groups considered are: anti-
thrombotics (antiplatelet or anticoagulants), lipid-low-
ering medications, thyroid medications and respiratory 
inhalers. These medications are commonly prescribed in 
older populations, have a strong evidence base in terms of 
efficacy and once started are usually recommended to be 
continued on a long-term basis. Furthermore, the conti-
nuity of these medications in prescribing and dispensing 
records has been the subject of study internationally—
allowing for comparison of results.11 25–32
We compare discontinuity of medication for each of the 
four medicine groups listed above in the GP prescribing 
record over a 6-month period between patients who had 
been admitted to hospital and a group of patients who 
had not been admitted to hospital. Second, we examine 
whether other patient and health-system factors are asso-
ciated with discontinuity of medication. A third objective 
is to assess whether documentation of prescribing of the 
specific medication in the hospital discharge summary 
record is associated with the presence of the same medi-
cation in the GP’s prescribing record in the following 
6 months.
MethODs
study design
We conducted a retrospective cohort study, adhering 
to the Strengthening the Reporting of Observational 
Studies in Epidemiology statement.33 Anonymous data 
were gathered using the general practice patient manage-
ment system which includes prescribing, demographic 
and clinical records and hospital supplied hospitalisation 
records.
Practice recruitment
A data extraction tool was developed with Socrates 
(providers of electronic health record (EHR) software 
to a majority of GP practices in Ireland). Following 
piloting of the extraction tool, a convenience sample of 
practices using Socrates EHR and receiving electronic 
hospital discharge communication (n=48) were invited to 
participate. Forty-four GP practices (response rate 91%) 
provided consent to take part in the study. Thirty prac-
tices were in the catchment area of the Dublin hospitals, 
with one in the North-East of Ireland. Eleven practices 
were in the catchment area of the Galway hospitals and 
two in the catchment area of the Cork hospitals. Partici-
pating GPs were awarded continuing professional devel-
opment points for their participation.
Medication classes
Four distinct patient cohorts were created based on the 
four medication classes: antithrombotics, lipid-lowering 
medications, thyroid medications and respiratory inhalers 
(figure 1). These medications are commonly prescribed 
in older populations and once commenced, are usually 
continued on a long-term basis.
study, enrolment and follow-up period criteria
The study period for each patient ranged from 1 January 
2012 to the date when the data were extracted from 
the GP practice; this varied between practices, with the 
Figure 1 Medication classes. *Anatomical Therapeutic Chemical (ATC) code groupings were used to ensure all component 
drugs within a class were included (eg, prasugrel, tecagrelor, etc). This chapter refers to each cohort by the first three figures of 
the ATC group.
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median time being 1 year and 180 days (figure 2). The 
study period included a 1-year enrolment period, and 
a 6-month follow-up period. The enrolment period 
for each medication class was the earliest 1-year period 
post 1 January 2012 over which a patient was continu-
ously prescribed medication from that medication class. 
Continuously prescribed was defined as two prescriptions 
issued at least 5 months apart. No hospitalisations were 
allowed during the enrolment period to avoid misclassi-
fying patients according to exposure. Patients could not 
be enrolled before 65 years of age and could be enrolled 
into more than one of the medication groups.
The start of the follow-up period, the period of time 
where discontinuity of medication was estimated, was 
marked by an index date. For patients who had been 
hospitalised, this was assigned as the day following 
discharge from hospital. For those individuals not expe-
riencing hospitalisation, the index date was randomly 
assigned following the enrolment period. This method of 
generating a comparison group has been used previously 
and is in line with assuming the medications are long-
term and unlikely to be discontinued.11
The follow-up period comprised a 6-month period 
following the index date. For patients who were read-
mitted to hospital during this 6-month period, the start 
of the follow-up period was reset until after the next 
discharge until a 6-month period free from further hospi-
talisation was established. For all hospitalised patients the 
180-day follow-up period was extended to take account of 
their length of stay of the relevant admission (reflecting 
the possibility that patients may have supplies of long-
term medication at home). A median length of stay for 
those hospitalised was added to the unexposed group 
follow-up period.
Patients who were categorised as deceased/inactive at 
the extraction date or who had no consultations after each 
follow-up period were excluded from the analyses. This 
avoided misclassifying a patient who may, for example, 
have died in hospital or was discharged to a long-term 
care facility and were not under the care of their previous 
GP.
explanatory variables of interest
For the first two objectives, hospitalisation was the main 
explanatory variable of interest. The electronic messaging 
system Healthlink provided discharge messages in 41 prac-
tices to signal a hospitalisation (inpatient stay, not emer-
gency department attendances). Hospitalisation was coded 
manually by research centre trained coders in four practices 
by examining the clinical records directly (one practice 
provided both Healthlink electronic discharge information 
and manually-coded discharge information). For the third 
objective, the main exposure variable was presence of medi-
cation in the hospital discharge summary note. This anal-
ysis was limited to hospitalised patients only. For all analyses, 
we examined whether patient and health-system variables 
might be associated with absence (primary analysis) or 
presence (secondary analysis) of medication in the GP 
prescribing—age, gender, public/private status, number 
of GP consultations, polypharmacy or multimorbidity.34–39 
Medication burden was calculated using RxRisk.34–40 All 
covariates were measured during the enrolment period.
Outcomes
The primary outcome was discontinuity of medication 
(failure to renew medication) in one of the four, pre-speci-
fied medication classes in the GP record over the follow-up 
period. Changes within Anatomical Therapeutic Chemical 
(ATC) class were allowed (eg, between different brands of 
inhalers). For each medication class, discontinuity of medi-
cation was compared between those who had been hospi-
talised and those who had not. We calculated univariable 
associations across the four medication classes and adjusted 
for important confounders and other explanatory variables 
of interest. The secondary outcome was presence of relevant 
medication in the patient’s general practice prescribing 
record following discharge from hospital. Again, this was 
estimated for each medication cohort.
sample size
The pilot phase and previous international studies in this 
area informed the calculation.11 12 Sample size calcula-
tion was based on 90% power to detect a 3% difference 
in the proportion of patients experiencing discontinuity. 
We assumed 11% of non-hospitalised patients have medi-
cations unintentionally discontinued. Additionally, a 4:1 
ratio of non-hospitalised to hospitalised patients (based 
on experience from the pilot phase) with a statistical 
significance of 5% was used. This gave a total requirement 
of 8410 participants in any one medication cohort group.
Plan of analysis
The number of patients at each stage of the study is 
reported, including those potentially eligible for enrol-
ment, those enrolled into each of the four cohorts and 
those available for analysis in the follow-up period. 
Reasons for removal are documented at each stage.
Descriptive statistics for the primary exposure (hospi-
talisation) and other explanatory variables are reported. 
For all statistical analyses, multilevel modelling was used 
Figure 2 Study enrolment and follow-up. *Discharge 
date was a random date applied to those not hospitalised. 
**Median length of stay of those hospitalised was added to 
those not hospitalised. 
 o
n
 12 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024747 on 4 June 2019. Downloaded from 
4 Redmond P, et al. BMJ Open 2019;9:e024747. doi:10.1136/bmjopen-2018-024747
Open access 
to examine the association between each exposure and 
outcome of interest, adjusting for patient and health-
system variables. In these models, individual patient, are 
nested within GP practices, giving rise to a (two level) 
multilevel model. Multilevel modelling allows for the fact 
that patients within any given practice could reasonably 
be expected to have more in common with each other 
than with those from a different practice—for instance in 
terms of prescriber patterns.
For the primary outcome, a multilevel logistic multivariate 
model was fitted to estimate the association between hospi-
talisation and discontinuity of medication for each medi-
cation class in turn, adjusted for patient and health system 
variables: age, gender, public/private status, Charlson score 
(comorbidity), number of repeat drug classes (polyphar-
macy) and number of enrolment period GP consultations. 
Results are reported as adjusted ORs (AOR) with 95% CI. 
These analyses were repeated using the number of hospital 
admissions (count variable) between the end of the enrol-
ment period and the beginning of the follow-up period as 
the main exposure, in order to assess the impact of repeated 
hospital admissions on discontinuity of medication in the 
GP prescribing record.
For the secondary analyses, multilevel logistic multi-
variate regression was again used to examine, for each 
medication group, the association between prescribing 
of the specified medication at discharge from hospital 
and presence of the medication in the subsequent GP 
prescribing history over the next 6 months. Models were 
adjusted for the same patient and health-service variables 
listed above. Unadjusted analyses, examining the associa-
tion between each explanatory variable and outcome in 
turn are reported for comparative purposes All analyses 
were performed using Stata V.14.41
Patient and public involvement
Patients were not involved in the conception, design or 
conduct of this research. We plan to disseminate the find-
ings to the public and patients through our contacts in 
patient representative bodies, the popular media and 
through the participating general practices.
results
Cohort flow
A total of 92 048 patients had their records extracted from 
the 44 recruited practices, of which 53 921 (58.6%) were 
removed immediately due to insufficient data (patients 
with sociodemographic data only, or who had no prescrip-
tions or consultations with the GP after 1 January 2012) 
(figure 3). A further 11 871 patients were removed due 
to not being prescribed any medications from the four 
drug groups of interest or having less than 12 months 
of follow-up data available to enable enrolment. The 
enrolment criteria were applied to the 26 256 remaining 
patients, creating four cohorts—antithrombotics (ATC 
classification system, B01) (n=13 684), lipid-lowering 
medications (ATC C10) (n=14 427), thyroid medications 
(ATC H03) (n=3484) and respiratory inhalers (ATC 
R03) (n=5227). Out of the whole group of patients, 7896 
(38.5%) were enrolled in one medicine group, 9184 
(44.8%) in two groups, 3074 (15.0%) in three groups and 
334 (1.6%) in all four groups.
Descriptive statistics
The demographics of the participants within the four 
cohorts of those available at the follow-up period are 
presented in table 1 (participant descriptives). Patients 
admitted to hospital tended to be slightly older, have 
more consultations with their GP and higher levels of 
polypharmacy and co-morbidity during the enrolment 
period than patients who remained out of hospital.
Figure 3 Participant flow chart.
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Among patients who were not hospitalised, the 
percentage of participants experiencing discontinu-
ation of medication at follow-up ranged from 8.5% 
(thyroid medications) to 17.0% (respiratory inhalers); 
and from 5.9% (thyroid medications) to 11.1% (respira-
tory inhalers) in those who were hospitalised. Levels of 
discontinuity were higher among those who had not been 
hospitalised in three of the four drug classes that were 
examined (table 1).
Over two-thirds of patients did not experience a 
hospital admission during follow-up across the four medi-
cation groups (table 2). Of those admitted to hospital, 
the percentage of patients experiencing a single admis-
sion ranged between 20.4% and 23.9% across the four 
medication groups. A minority of patients experienced 
multiple medical admissions (table 2).
univariable and multivariable associations
There is no difference in terms of likelihood of disconti-
nuity for lipid-lowering and antithrombotic drugs between 
hospitalised and non-hospitalised patients. Hospitalisa-
tion is associated with less odds of discontinuity of long 
term medication on those prescribed thyroid medications 
and respiratory inhalers after adjustment for important 
confounders (table 3—analysis of primary outcome). For 
all four medication groups, older patients are more likely 
to experience discontinuity of medication than younger 
patients, with the odds of discontinuity increasing by 
between 3% and 6% per year (p<0.001). Private patients 
(those who paid for their own prescriptions and their GP 
visits out of pocket) have the strongest association with 
discontinuity across all four medicine groups with AOR 
varying between 3.75, (95% CI 2.84 to 4.96) for respira-
tory inhalers and 11.67, (95% CI 8.02 to 16.96) for thyroid 
medications (table 3). Number of consultations, multi-
morbidity, number of repeat medications and gender are 
not associated with an increased odds of discontinuity.
In a sub-group analysis of the antithrombotics (B01) 
category, we found that antiplatelets were independently 
associated with increased discontinuation after hospi-
talisation (AOR 1.30, 95 % CI 1.12, 1.52), while for 
warfarin and new oral anticoagulants (NOACs), no asso-
ciation between hospitalisation and discontinuation was 
observed (AOR 0.97, 95% CI 0.68 to 1.39). For both anti-
platelets and NOACs, older age and private patients were 
independently associated with discontinuation (online 
supplementary table 1).
repeated hospital admissions
To assess the impact of repeated hospital admissions, 
models were re-estimated with the hospital exposure 
defined as the number of hospital admissions (count) 
between the end of the enrolment period and the 
beginning of the follow-up period. For antithrombotics, 
lipid-lowering medications and thyroid medications, 
there was no evidence of a statistically significant associ-
ation between the number of admissions to hospital and 
discontinuity of medication in the 6-month follow-up 
period. However, for respiratory inhalers, the odds of 
discontinuity of medication fell by an estimated 13% 
per additional admission to hospital after adjusting for 
confounders (AOR 0.87, (95% CI 0.76 to 0.99), p=0.03). 
For further details see online supplementary table 2 
(Repeated admissions analysis).
Impact of medication specified in patient’s hospital discharge 
summary
Recording of medication on the hospital discharge 
summary was relatively poor, with only 39.2% to 47.4% 
of patients having the relevant medication group docu-
mented across the four medication groups. Medication 
recording had improved at 6 months postdischarge, being 
present in 89.2% to 94.7% of patient’s GP clinical records 
across medication groups (table 4—documentation of 
medication at discharge and in the GP record). Having 
medication listed on hospital discharge summary was 
independently associated with medication being present 
on the GP record as 6 months follow-up for both lipid-low-
ering drugs and respiratory inhalers. Private patients 
were significantly less likely to have the relevant medica-
tion in their GP prescribing record in the 6-month period 
Table 2 Number of hospital admissions following enrolment for patients assessed for medication discontinuity at follow-up
Medication group
(no patients 
enrolled)
Antithrombotics
(B01) (n=13 684)
Lipid-lowering
(C10) (n=14 427)
Thyroid meds
(H03) (n=3484)
Respiratory inhalers 
(R03) (n=5227)
No patients at end of follow-up period
  0 6152 (69.44%) 6944 (72.59%) 1641 (73.69%) 2110 (66.41%)
  1 2011 (22.70%) 1958 (20.45%) 457 (20.52%) 761 (23.95%)
  2 448 (5.06%) 419 (4.38%) 90 (4.04%) 200 (6.30%)
  3 140 (1.58%) 139 (1.45%) 26 (1.17%) 60 (1.89%)
  4 25 (0.28%) 50 (5.23%) 5 (0.23%) 27 (0.85%)
  5 8 (0.09%) 24 (0.25%) 6 (0.27%) 5 (0.16%)
  6 7 (0.08%) 8 (0.09%) 1 (0.04%) 5 (0.16%)
  >6 23 (0.26%) 24 (0.25%) 1 (0.04%) 14 (0.44%)
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following discharge from hospital than public patients 
(table 5—analysis of secondary outcome).
DIsCussIOn
Principal findings
Discontinuation of medication in patients who had 
been recently hospitalised ranged from 6% to 11% 
for commonly prescribed, evidence-based medicines, 
compared with 5%–17% for non-hospitalised patients. 
Patients prescribed thyroid medications and respira-
tory inhalers, who experienced hospitalisation, actually 
had a lower risk of discontinuity. Public or private care 
played a significant role in the likelihood of medication 
being discontinued with the odds of discontinuation 
significantly higher for private patients than non-pri-
vate patients in all medication groups. Increasing age 
is independently associated with an increased odds of 
discontinuation of medication. Lastly, recording of 
mediation on hospital discharge summaries is incom-
plete, being present in less than 50% of discharged 
patients for all four medication groups. Presence of 
medication on hospital discharge summaries is associ-
ated with continuity on the GP prescribing record at 
6 months for lipid lowering medication and respiratory 
inhalers.
Previous research
Findings from this observational study differs from similar 
studies in the USA, both in the magnitude of discontinua-
tion: reported to be between 12% and 19% for thyroid and 
antithrombotic medications; and in terms of the impact of 
hospitalisation, with hospitalisation being independently 
associated with discontinuation, when assessed using phar-
macy dispensing data.8–10 41 The impact of hospitalisation 
appears to be context and health system-specific, with some 
studies not finding a relationship between discontinuity 
and hospitalisation.42–44 We found that increased number 
of medications was not associated with discontinuation; in 
the respiratory inhalers group patients were less likely to 
be discontinued if they had increased numbers of medica-
tions.34 37–39 45–47 Like other studies we found that increasing 
age was independently associated with an increased discon-
tinuity post discharge.19
A particularly interesting finding in our study is 
the marked difference between publicly funded and 
privately funded patients. Private patients were found to 
have a consistent pattern of discontinuity independent 
of other patient and health system factors (table 3). 
Similarly, in hospitalised patients, being a private 
patient was associated with discontinuity of medica-
tion recording in their GP record and significantly 
more likely at 6 months follow-up. There are possible 
explanations for this finding. Private patients are not 
required to have their hospital discharge prescription 
transcribed by their GP and may proceed directly to 
the pharmacy, thereby appearing as if their medica-
tion has been discontinued by our method of outcome 
calculation. Nevertheless, lack of continuity in the GP 
record raises concerns about completeness of the infor-
mation a GP in relation to a patient’s medication file, 
monitoring requirements, potential drug-to-drug inter-
actions and other potential prescribing errors.
In keeping with findings from other studies, the quality 
of prescribing information contained in hospital discharge 
summaries was incomplete for over half of discharged 
patients, with the omission of essential medications 
common.18 35 Furthermore, lack of medication reconcilia-
tion on hospital discharge appeared to persist for at least 
6 months in general practice medication records.21 The 
hospital discharge summary used to determine discharge 
medication in this study is only one element of the infor-
mation normally provided to patients at discharge from 
hospital. A supplementary discharge prescription may also 
be provided.35 Therefore, a discrepancy may arise between 
the hospital discharge summary and additional discharge 
prescription, as hospital doctors make judgements about 
what to include/exclude from discharge prescriptions.48 
These parallel methods of providing post-discharge medica-
tion information is a cause for concern and likely enhance 
risks of medication discontinuity.
While lack of medication reconciliation following 
hospital discharge may be one possible explanation 
for the reported discontinuity, there are other possible 
explanations, most commonly poor patient adherence. A 
recent UK study of statin adherence reported discontin-
uation rates of 27% at 1 year in those prescribed statins. 
Notably this was examining primary non-adherence 
(failure to fill an initial prescription) as distinct from what 
may be secondary non-adherence (inadequate medi-
cation possession over a defined period of time) in this 
cohort).49 50 The factors that influence adherence may 
be patient, therapy, physician or health system related.51 
While this study was able to control for some of these 
factors (demographics, comorbidities, public/private 
care status) others were not recorded (socioeconomic 
status, side-effects, individual physician behaviour and 
access to healthcare).
Lastly, inadequate adherence (and the related terms 
non-compliance and non-concordance) may take many 
forms, for example, non-filling of prescriptions, altering 
doses, stopping/starting. This study reported a varying 
discontinuity rate across the four drug classes (lower in 
antithrombotics and higher in respiratory inhalers). The 
variation between medication classes observed here may 
be explained by disease-specific issues (eg, altering doses 
of thyroxine replacement due to undulating severity of 
disease meaning repeat prescriptions are not required; 
asymptomatic asthma patients not needing to take bron-
chodilator inhalers), evolving or clinical considerations 
such as the changing risk benefit profile of an antithrom-
botic in a patient with a high risk of falls.52
strengths and limitations of study
This is the largest Irish study to date to examine the effect 
of hospitalisation on the continuity of evidence-based 
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medication in the GP prescribing record. It is also the 
first study to systematically use GP prescribing records (as 
opposed to pharmacy dispensing records) and includes 
details of both private and public patients, unique features 
of the mixed public/private health system in Ireland. 
The recruitment of GP practices was not limited to one 
geographically area/hospital catchment and the inclusion 
of multiple hospitals allowed comparison of messaging 
standards and their impact on prescribing continuity, 
enhancing the generalisability of the findings.
There are several limitations to this study. The medi-
cation groups were specifically chosen to be evidence-
based and long-term in their usage and the establishment 
of an enrolment period of continuous usage over 1 year 
further ensures the pattern of ongoing use. However, the 
primary outcome of discontinuation of medication was 
applied to a prescribing database and does not contain 
information about indication or therapeutic intent, for 
example intentional discontinuation of statins in end-of-
life patients. In addition, the nuances between different 
medications (eg, warfarin and aspirin) is lost by grouping 
in larger ATC classes. Differential discontinuation within 
the antithrombotic (B01) class of drugs was observed in 
a sub-group analysis, with antiplatelet discontinuation 
associated with hospitalisation, while for NOACs hospi-
talisation was not associated with discontinuation. These 
findings need to be treated with caution, as they were not 
pre-specified and the magnitude of association with anti-
platelets is relatively modest.
The nature of data collection and the dataset itself also 
incur limitations. Hand-written prescriptions were not 
captured by this data collection technique. The follow-up 
of participants from enrolment through to outcome calcu-
lation also required assumptions to be made in preparing 
the data for analysis. However, the methods have been used 
previously, and are in line with the underlying assumption 
that there should be no difference between groups with 
both having 100% persistence of the medication in the GP 
record. These findings reflect the Irish healthcare system 
and may not be applicable in other systems with greater or 
lesser usage of electronic communication between primary/
secondary care or developed reconciliation systems. Lastly, 
the recording of hospitalisation is likely to be variable within 
practices, with the Healthlink service employed differently by 
hospitals with the possibility of misclassification of exposed 
individuals. These methodological and data issues were 
explored in the sensitivity analysis with no change in the 
overall findings.
Clinical and healthcare policy implications
Medication reconciliation, the process of creating the 
most accurate list of medications at transition points, 
has been advocated by a number of different profes-
sional and accrediting bodies internationally. Ensuring 
the accuracy of medication information at transitions 
is reliant on good communication. The quality of elec-
tronic discharge communication received by general 
practices and the possible association with inappropriate 
discontinuation of evidence-based medication suggests 
more emphasis needs to be placed on improving the 
quality of discharge communication. The health service 
executive’s ePrescribing initiative and eScript pilot proj-
ects are efforts to improve the transfer of medication 
information.53 54
Future efforts should focus on identifying high-risk indi-
viduals who are receiving medications that would be the 
best targets for reconciliation studies and interventions. 
Recent efforts have been made to develop a consensus 
about high risk medications and methods of assessing the 
potential severity of medication omission.55
COnClusIOns
Discontinuity of evidence-based long-term medication 
is common. Increasing age and private medical care are 
independently associated with a higher risk of medica-
tion discontinuity. Hospitalisation was not associated with 
discontinuity but less than half of hospitalised patients had 
medication recorded on their hospital discharge summary. 
System based solutions that include ePrescribing are 
needed to enhance the transfer of medication information 
across the primary/secondary care interface.
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